BMC cancer · 2026
Effectiveness and safety of PD-1/PD-L1 inhibitors plus lenvatinib with or without Gemox chemotherapy in advanced intrahepatic cholangiocarcinoma.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Li Shuofeng, Yu Guanhua, Wang Shanshan, Wang Mingming, Zhu Chengpei, Piao Mingjian, Xun Ziyu, Li Chengjie, Sun Boyu, Chao Jiashuo, Pan Jie, Zhou Kang, Chen Xinyuan, Yang Xiaobo, Zhao Haitao
Аннотация
BACKGROUND AND AIMS: Advanced intrahepatic cholangiocarcinoma (ICC) is characterized by a poor prognosis. This study evaluated the efficacy and safety of programmed cell death protein 1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitors combined with lenvatinib, with or without gemcitabine and oxaliplatin (Gemox) chemotherapy.
METHODS: A retrospective cohort analysis was performed on patients with advanced ICC who received treatment with PD-1/PD-L1 inhibitors and lenvatinib, with or without Gemox chemotherapy, between February 2017 and February 2024. Outcomes included progression-free survival (PFS), overall survival (OS), objective response rate (ORR), disease control rate (DCR), and safety.
RESULTS: The study included 107 patients, comprising 67 patients treated with PD-1/PD-L1 inhibitors and lenvatinib (P-L group) and 40 patients treated with PD-1/PD-L1 inhibitors, lenvatinib, and Gemox chemotherapy (P-L-G group). In comparison to the P-L group, the P-L-G group had longer median OS (16.4 months vs. 13.7 months, P = 0.047) and median PFS (11.1 months vs. 5.6 months, P = 0.004). Furthermore, the P-L-G group had a higher ORR (60.00% vs. 22.39%) and DCR (85.00% vs. 73.13%). All patients experienced adverse events (AEs), with 33 patients (49.25%) in the P-L group and 22 patients (55.00%) in the P-L-G group reporting grade 3-4 AEs. No grade 5 AEs were observed, and all AEs were manageable. Meanwhile, among patients with TP53 mutations (P = 0.048), KRAS mutations (P = 0.037), IDH1 mutations (P = 0.033), or BAP1 wild-type status (P = 0.039 and P = 0.022), the P-L-G group exhibited a more favorable prognosis compared to the P-L group.
CONCLUSIONS: Advanced ICC patients may derive greater benefit from the triple combination therapy of PD-1/PD-L1 inhibitors, lenvatinib, and Gemox chemotherapy without an increase in AEs. This regimen holds potential as an effective first-line treatment for advanced ICC.
METHODS: A retrospective cohort analysis was performed on patients with advanced ICC who received treatment with PD-1/PD-L1 inhibitors and lenvatinib, with or without Gemox chemotherapy, between February 2017 and February 2024. Outcomes included progression-free survival (PFS), overall survival (OS), objective response rate (ORR), disease control rate (DCR), and safety.
RESULTS: The study included 107 patients, comprising 67 patients treated with PD-1/PD-L1 inhibitors and lenvatinib (P-L group) and 40 patients treated with PD-1/PD-L1 inhibitors, lenvatinib, and Gemox chemotherapy (P-L-G group). In comparison to the P-L group, the P-L-G group had longer median OS (16.4 months vs. 13.7 months, P = 0.047) and median PFS (11.1 months vs. 5.6 months, P = 0.004). Furthermore, the P-L-G group had a higher ORR (60.00% vs. 22.39%) and DCR (85.00% vs. 73.13%). All patients experienced adverse events (AEs), with 33 patients (49.25%) in the P-L group and 22 patients (55.00%) in the P-L-G group reporting grade 3-4 AEs. No grade 5 AEs were observed, and all AEs were manageable. Meanwhile, among patients with TP53 mutations (P = 0.048), KRAS mutations (P = 0.037), IDH1 mutations (P = 0.033), or BAP1 wild-type status (P = 0.039 and P = 0.022), the P-L-G group exhibited a more favorable prognosis compared to the P-L group.
CONCLUSIONS: Advanced ICC patients may derive greater benefit from the triple combination therapy of PD-1/PD-L1 inhibitors, lenvatinib, and Gemox chemotherapy without an increase in AEs. This regimen holds potential as an effective first-line treatment for advanced ICC.
Предметные рубрики MeSH
HumansQuinolinesCholangiocarcinomaPhenylurea CompoundsAntineoplastic Combined Chemotherapy ProtocolsFemaleRetrospective StudiesAgedMiddle AgedMaleBile Duct NeoplasmsDeoxycytidineImmune Checkpoint InhibitorsOxaliplatinProgrammed Cell Death 1 ReceptorGemcitabineB7-H1 AntigenAdultOrganoplatinum Compounds